{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"33","value":"4.382"}]}],"title":"Cycle 0 Day1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"39","value":"8.846"}]}],"title":"Cycle 1 Day 1"}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"}],"units":"Participants"}],"dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants received an initial priming dose of 600 microgram per kilogram elranatamab subcutaneously on Cycle 0 Day 1 (7 days prior to Cycle 1 Day 1). During treatment cycle, participants were administered 1000 microgram per kilogram elranatamab weekly during each cycle (each cycle was of 3 weeks).","id":"OG000","title":"Elranatamab"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Pharmacokinetic parameter analysis population was defined as all enrolled participants treated who did not have protocol deviations influencing PK assessment and had sufficient information to estimate at least 1 of the PK parameters of interest.","reportingStatus":"POSTED","timeFrame":"Cycle 0: from Cycle 0 Day 1 (pre dose to the next dose of study intervention) [maximum of 9 days]; Cycle 1: from Cycle 1 Day 1 (pre dose to the next dose of study intervention) [maximum of 9 days]","title":"Maximum Observed Serum Concentration (Cmax) of Elranatamab","type":"SECONDARY","unitOfMeasure":"Micrograms per milliliter"}